Table 1 Patient and tumour characteristics

From: Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

 

Anastrozole arm

Fulvestrant arm

 

N =61 (%)

N =59 (%)

Age (years)

Median (range)

69 (54–86)

71 (51–91)

ECOG PS

0

53 (86.9)

49 (83.1)

1

8 (13.1)

10 (16.9)

Tumour size (mm)

Median (range)

45 (25–90)

50 (30–110)

T classification

T2

43 (70.5)

32 (54.2)

T3

9 (14.8)

13 (22.0)

T4

2 (3.3)

8 (13.6)

T4a

0 (0)

1 (1.7)

T4b

6 (9.8)

4 (6.8)

T4c

1 (1.6)

1 (1.7)

N classification

N0

39 (63.9)

29 (49.2)

N1

22 (36.1)

29 (49.2)

NX

0 (0)

1 (1.6)

Histology

Ductal invasive carcinoma

45 (73.8)

39 (66.1)

Lobular invasive carcinoma

14 (23.0)

19 (32.2)

Mucinous adenocarcinoma

2 (3.3)

1 (1.7)

Histologic grades

I

11(18.0)

8 (13.6)

II

45 (73.8)

44 (74.6)

III

3 (4.9)

5 (8.5)

Not available

2 (3.3)

2 (3.4)

Receptor status

ER+

61 (100)

59 (100)

PR+

54 (88.5)

55 (93.2)

PR−

6 (9.8)

3 (5.1)

PR not available

1 (1.6)

1 (1.7)

HER2 a

Positive

4 (6.6)

3 (5.1)

Negative

55 (90.2)

55 (93.2)

Missing

2 (3.3)

1 (1.7)

  1. Abbreviations: ECOG PS=performance status; ER=oestrogen receptor; PR=progesterone receptor.
  2. aHER2 positive if immunohistochemistry 3+ or if FISH amplified.
Back to article page